The University of Oxford launched a call to recruit more than 10,000 volunteers to test a coronavirus vaccine, after completing a first phase.

“Phase I testing of healthy adult volunteers began in April. More than 1,000 vaccines have been completed and follow-up is currently ongoing. The next study will enroll up to 10,260 adults and children and will involve several partner institutions across the country,” informed the institution.

The university said vaccination work is progressing rapidly and that phase II will expand the age range of people for whom the vaccine is being evaluated to include a small number of adults ages 56 to 69 and another smaller group. even over 70 years old and children from 5 to 12 years old.

The researchers will evaluate the immune response to the vaccine in people of different ages, to determine if there is a variation in the response of the immune system in older people or children.

While phase III of the study will involve evaluating how the vaccine works in a large number of people over 18 years of age.

“This group will evaluate how well the vaccine works to prevent people from becoming infected and not getting sick with the virus.”

The University detailed that adult participants in the Phase II and Phase III groups will be randomized to receive one or two doses of the vaccine called ChAdOx1 nCoV-19 or a licensed vaccine (MenACWY) to be used as a control for comparison.

“ChAdOx1 nCoV-19 is made from a virus (ChAdOx1), which is a weakened version of a common influenza virus (adenovirus) that causes infections in chimpanzees, which has been genetically engineered to make it impossible for it to replicate in humans. .

“Clinical studies are progressing very well and we are now initiating studies to assess how well the vaccine induces immune responses in older adults and to assess whether it can provide protection in the broader population,” said Andrew Pollard, head of the Vaccine Group at Oxford.

For her part, Sarah Gilbert, a professor of vaccinology at the Jenner Institute, added that the vaccine test team has been working hard to assess the safety and immunogenicity of ChAdOx1 nCoV-19 and prepare to assess the vaccine’s efficacy.

“We have already had a lot of interest from people over 55 who were not eligible to participate in the phase I study and now we will be able to include older groups to continue with the vaccine evaluation. We will also include more study sites, in different parts of the country, “he added.